Oxeia Biopharmaceuticals
Rest is not enough

In The News

The Hill, February 14, 2020 Mild Traumatic Brain Injuries Can Lead to a Lifetime of Health Issues for Soldiers
by Vishal Bansal, MD

Concussions are a serious health problem in the military. In January, 2020, 109 US servicemen in Iraq suffered traumatic brain injury from Iranian airstrikes. But this is just the latest occurrence; in the last 9 years over 413,000 troops were diagnosed with TBI. In this article, Oxeia co-founder and chief scientific officer, Vishal Bansal, calls on Congress, the Pentagon, and the medical establishment to increase their commitment to finding an effective treatment to protect our proud members of the military.
Fortune, January 19, 2020 Fortune contributor Michael Lev-Ram acknowledges Richard Sherman’s numerous accomplishments in football in his recent article - from his "best cornerback of the decade," to his fifth invitation to play in the Pro Bowl to his role in helping bringing the San Francisco 49ers to Super Bowl LIV – but Lev-Ram devotes more ink telling of Sherman's role as a tech investor.

Lev-Ram observes that Sherman is emerging as a Silicon Valley venture capitalist with a purpose, finding new solutions to address health and safety issues in sports. He gives a special call-out to Sherman’s role with Oxeia Biopharmaceuticals, "a drug company that’s experimenting with a drug that mitigates the effect of concussions right after they happen."

Sherman recently joined Decibel, a VC backed by Cisco, as an investor and advisor. While Decibel will not focus specifically on health and safety issues, Sherman's presence may encourage investing in companies with this focus.
San Diego, CA - November 12, 2019 Oxeia Biopharmaceuticals' CEO Michael Wyand, DVM, PhD, will participate in a panel discussion on redefining therapeutics areas and new technology paradigms at the Genesis 2019 Life Sciences Conference in London in December. Oxeia is preparing for the launch of Phase 2 human clinical studies for its therapeutic drug to treat concussions.
CNBC, August 11, 2019 49ers star Richard Sherman is betting on software and against concussions as he dives into start-ups. One of the startups is Oxeia Biopharmaceuticals, which is developing a concussion drug that would treat the immediate symptoms and the underlying damage.
The Senior Citizens Magazine, June 1, 2019 Seniors suffer from concussions at far higher rates than any other group. Oxeia Biopharmaceuticals is working on a drug that will treat concussions. They have completed Phase 1 trials and are preparing for human trials.
CBS Sports Radio, March 20, 2019 San Francisco 49ers cornerback and Oxeia board member Richard Sherman stops by the Tiki and Tierney Show to talk about concussions and Oxeia's research.
San Francisco Chronicle, February 19, 2019 SF 49er and Oxeia board member Richard Sherman speaks his mind about the NFL's concussion policy in his San Francisco Chronicle op-ed. Tells readers concussion medicines are under development.
S+P, December 18, 2018 Leading market analysis publication interviews Oxeia CEO Michael Wyard about how Oxeia works, clinical trials, and anticipated market.
San Diego Business Journal, December 10, 2018 Oxeia Leading the Pack on Potential Concussion Treatments. Oxeia's co-founder and chief business officer, Kartik Shah explains that, "Oxeia's drug (OXE-103) promotes the generation of new synapses, which could play a role in connectivity and cognition." Oxeia is raising $3million for mid-stage human trials, while others in the space are in the preclinical stage. According to Shah, "OXE-103 is targeting multiple pathways, upping the chances of success."
Boston Globe, November 23, 2018 Oxeia is one of handful of startups experimenting with drugs that could treat concussions.
September 6, 2017 Oxeia Biopharmaceuticals, Inc. Announces Appointment of Dr. Michael Wyand as Chief Executive Officer
August 27, 2017 FiercePharma Article: Richard Sherman Joins Oxeia Advisory Board
August 23, 2017 Richard Sherman, NFL All-Pro, Joins Oxeia Biopharmaceuticals Advisory Board
August 2, 2017 Oxeia Biopharmaceuticals Announces Clinical Advancement of Concussion Treatment
December 14, 2016 Christopher Nowinski Joins Oxeia Biopharmaceuticals Advisory Board
January 21, 2016 Oxeia Biopharmaceuticals, Inc. Advancing Development of OXE-103 for the Treatment of Concussions